Cognition Therapeutics In... (CGTX)
NASDAQ: CGTX
· Real-Time Price · USD
1.54
-0.12 (-7.23%)
At close: Aug 15, 2025, 3:59 PM
1.56
0.97%
After-hours: Aug 15, 2025, 06:58 PM EDT
-7.23% (1D)
| Bid | 1.54 |
| Market Cap | 113.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.3M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -2.34 |
| Forward PE | -2.7 |
| Analyst | Buy |
| Ask | 1.56 |
| Volume | 13,195,637 |
| Avg. Volume (20D) | 9,088,216 |
| Open | 1.67 |
| Previous Close | 1.66 |
| Day's Range | 1.52 - 1.97 |
| 52-Week Range | 0.22 - 1.97 |
| Beta | 1.00 |
About CGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
+10.91%
Cognition Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
4 days ago
+28.1%
Cognition Therapeutics shares are trading higher after the company announced it received final minutes from the FDA pertaining to the end-of-Phase 2 meeting that confirmed the proposed design of the Phase 3 program may support a New Drug Application filing for zervimesine as a treatment for Alzheimer's disease.
